Skip to main content
48°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Candel Therapeutics, Inc. - Common Stock
(NQ:
CADL
)
5.640
-0.010 (-0.18%)
Streaming Delayed Price
Updated: 1:12 PM EDT, Apr 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Candel Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients
March 27, 2025
Candel Therapeutics' CAN-2409 extended survival in NSCLC patients, with biomarker data showing enhanced response in non-squamous cases and a strong safety profile.
Via
Benzinga
Candel Therapeutics Shares Are Down Today: What's Going On?
March 27, 2025
Candel Therapeutics, Inc. (NASDAQ: CADL) shares are are trading lower Thursday after the company released final survival data from its phase 2a clinical trial of CAN-2409.
Via
Benzinga
Candel’s Final Survival Data From Lung Cancer Drug Trial Lifts Stock After-Hours, Fuels Retail Optimism
March 27, 2025
The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years.
Via
Stocktwits
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week
February 23, 2025
Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.
Via
Stocktwits
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
February 20, 2025
Via
Benzinga
How Is The Market Feeling About Candel Therapeutics?
January 08, 2025
Via
Benzinga
Major Indexes Falter; Dow Drops Over 550 Points
February 20, 2025
The Dow Jones Industrial Average is down 556 points midday, heading for its worst daily percentage loss since mid January, while the S&P 500 Index and Nasdaq Composite sit firmly in the red as well.
Via
Talk Markets
Topics
Stocks
Stocks / Equities
Exposures
US Equities
Let's uncover which stocks are experiencing notable gaps during today's session.
February 20, 2025
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.
Via
Chartmill
Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice
February 20, 2025
CAN-2409 could become a “best-in-class therapy” for borderline resectable pancreatic ductal adenocarcinoma, according to the analyst.
Via
Stocktwits
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
February 19, 2025
Via
Benzinga
Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call
February 07, 2025
The analyst noted that CAN-2409's early data in prostate cancer suggests the potential for a meaningful breakthrough, given the lack of significant advancements in available treatments.
Via
Stocktwits
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
February 07, 2025
Via
Benzinga
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
December 20, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 13, 2024
Via
Benzinga
What's Going On With Candel Therapeutics Shares Friday?
December 13, 2024
Candel shares are moving lower on Friday after the company priced its $80 million underwritten public offering of shares and pre-funded warrants.
Via
Benzinga
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
December 13, 2024
Via
Benzinga
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
December 13, 2024
Via
Benzinga
Candel Therapeutics Shares Are Up Today: What's Going On?
December 12, 2024
Candel Therapeutics, Inc. (NASDAQ: CADL) shares are trading higher Thursday potentially driven by continued momentum following the company's announcement of positive phase 3 trial results for its...
Via
Benzinga
Gamestop, Adobe, Meta, Candel Therapeutics, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
December 11, 2024
The stock market experienced a wave of optimism on Wednesday, driven by the latest inflation report. The Nasdaq 100 surged 1.7%, achieving a new record high.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
December 11, 2024
Via
Benzinga
Crude Oil Jumps 2%; Macy's Lowers Earnings Forecast
December 11, 2024
Via
Benzinga
Exposures
Fossil Fuels
10 Health Care Stocks Whale Activity In Today's Session
December 11, 2024
Via
Benzinga
Nasdaq Surges Over 1%; US Inflation Rises In-Line With Expectations
December 11, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Candel Therapeutics Stock Surges Over 100% - Here's Why
December 11, 2024
Candel Therapeutics reports phase 3 trial success for CAN-2409 in prostate cancer, showing improved disease-free survival and safety consistency.
Via
Benzinga
Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug
December 11, 2024
The company is hoping to eventually launch the first major new treatment for localized prostate cancer in over 20 years.
Via
Investor's Business Daily
CADL Stock Earnings: Candel Therapeutics Reported Results for Q2 2024
August 13, 2024
Candel Therapeutics just reported results for the second quarter of 2024.
Via
InvestorPlace
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
July 18, 2024
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins.
Via
Benzinga
Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
June 14, 2024
Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
Via
News Direct
7 A-Rated Biotech Stocks Worth Betting on in June
June 14, 2024
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation.
Via
InvestorPlace
Why BioRestorative Therapies Stock Is Moving Higher Thursday
June 13, 2024
BioRestorative Therapies announced before the market opened on Thursday that it engaged in substantive licensing discussions with a regenerative medicine company related to its ThermoStem Metabolic...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.